pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLCpulmo-2602Research ArticleОБЗОРЫREVIEWСпирива - эффективный препарат, уменьшающий одышку и частоту обострений при хронической обструктивной болезни легких (данные клинических испытаний)Spiriva is an effective drug reducing dyspnoe and exacerbation rate in COPD (clinical search findings)ОвчаренкоC. И.OvcharenkoS. I.ГоликоваЕ. П.GolikovaE. P.Московская медицинская академия им. И.М.СеченоваРоссия20030209202106103107Copyright © Овчаренко C.И., Голикова Е.П., 20212021Овчаренко C.И., Голикова Е.П.Ovcharenko S.I., Golikova E.P.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2602
.
ReferencesСинопальников А .И ., Клячкина И.Л. Тиотропиум бромид: новые возможности в лечении хронической обструктивной болезни легких. Рос. мед. журн. 2001; 9 (15): 658.Синопальников А .И ., Клячкина И.Л. Тиотропиум бромид: новые возможности в лечении хронической обструктивной болезни легких. Рос. мед. журн. 2001; 9 (15): 658.American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. CareMed. 1995; 152: S77-S121; 2001; 163: 1256-1276.American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. CareMed. 1995; 152: S77-S121; 2001; 163: 1256-1276.Barnes P. Tiotropium bromide: a new long-acting anticholinergic bronchodilator. In: Barnes P., Buist A.S., eds. The rôle of anticholinergics in chronic obstructive pulmonary disease and chronic asthma. Macclesfied Cheshire, UK: Gardiner-Caldwell Communications Limited; 1997. 126-136.Barnes P. Tiotropium bromide: a new long-acting anticholinergic bronchodilator. In: Barnes P., Buist A.S., eds. The rôle of anticholinergics in chronic obstructive pulmonary disease and chronic asthma. Macclesfied Cheshire, UK: Gardiner-Caldwell Communications Limited; 1997. 126-136.Briggs D.D., Kuritzky L., Boland C. et al. Early détection and management of COPD: Guidelines from the National COPD Awareness Panel (NCAP). J Respir Dis. 2000; 21: S1-S21.Briggs D.D., Kuritzky L., Boland C. et al. Early détection and management of COPD: Guidelines from the National COPD Awareness Panel (NCAP). J Respir Dis. 2000; 21: S1-S21.Casabury R., Mahler D.A., Jones P.W. et al. A long-term élévation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217-224.Casabury R., Mahler D.A., Jones P.W. et al. A long-term élévation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217-224.COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease a combination of ipratropium and albuterol is more effective than either agent alone. A 65-day multicenter trial. Chest 1994; 105: 1411-1419.COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease a combination of ipratropium and albuterol is more effective than either agent alone. A 65-day multicenter trial. Chest 1994; 105: 1411-1419.The COPD guidelines group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52 (suppl.5): S1-S28.The COPD guidelines group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52 (suppl.5): S1-S28.Doherty D.E. Management of the Symptomatic Patient. Clin. Cornerstone 2003; 5(1): 17-27.Doherty D.E. Management of the Symptomatic Patient. Clin. Cornerstone 2003; 5(1): 17-27.Donohue J.F., van Noorcl J.A., Bateman E. et at. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.Donohue J.F., van Noorcl J.A., Bateman E. et at. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.Friedman M ., Auerbach D., Campbell S. et al. Tiotropium in patients with COPD. Am. J. Respir. Crit. Care Med. 1998; 157: A804.Friedman M ., Auerbach D., Campbell S. et al. Tiotropium in patients with COPD. Am. J. Respir. Crit. Care Med. 1998; 157: A804.Friedman M ., Serby C.W., Shailendra S.M. et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone. Chest 1999; 115: 635-641.Friedman M ., Serby C.W., Shailendra S.M. et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone. Chest 1999; 115: 635-641.Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (Updated 2003). National Institutes of Health; National Heart, Lung and Blood Institute; 2003.Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (Updated 2003). National Institutes of Health; National Heart, Lung and Blood Institute; 2003.Greefhorst A.P.M ., Vincken W., van Noord J.A. et al. Improvement in perceived dyspnea in COPD patients receiving tiotropium vs ipratropium bromide (atroventT). Eur. Respir. J. 2000; 16 (suppl.31): 54s.Greefhorst A.P.M ., Vincken W., van Noord J.A. et al. Improvement in perceived dyspnea in COPD patients receiving tiotropium vs ipratropium bromide (atroventT). Eur. Respir. J. 2000; 16 (suppl.31): 54s.Gross N.J., Skorodin M.S. Anticholinergic antimuscarinic bronchodilators. Am. Rev. Respir. Dis. 1984; 129: 856-870.Gross N.J., Skorodin M.S. Anticholinergic antimuscarinic bronchodilators. Am. Rev. Respir. Dis. 1984; 129: 856-870.Guyatt G.H., Townsend M ., Pugsley S.O. et al. Bronchodilators in chronic airflow limitation. Effects on airway function, exercise capacity, and quality of life. Am. Rev. Respir. Dis. 1987; 135: 1069-1074.Guyatt G.H., Townsend M ., Pugsley S.O. et al. Bronchodilators in chronic airflow limitation. Effects on airway function, exercise capacity, and quality of life. Am. Rev. Respir. Dis. 1987; 135: 1069-1074.Ikeda A., Nishimura K., Koyama H. et al. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: comparison with ipratropium bromide alone. Chest 1995; 107: 401-405.Ikeda A., Nishimura K., Koyama H. et al. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: comparison with ipratropium bromide alone. Chest 1995; 107: 401-405.Jones P. W., Koch P., Menjoge S.S et al. The Impact of COPD exacerbations on health-related quality of life (health status) is attenuated by tiotripium. Am. J. Respir. Crit. Care Med. 2001; 163 (5): A771.Jones P. W., Koch P., Menjoge S.S et al. The Impact of COPD exacerbations on health-related quality of life (health status) is attenuated by tiotripium. Am. J. Respir. Crit. Care Med. 2001; 163 (5): A771.Kotch A., Mejoge S.S., Serby C.W. et al. Nocturnal symptoms and severity of disease in COPD. Am. J. Respir. Crit. Care Med. 2001; 163 (5): A906.Kotch A., Mejoge S.S., Serby C.W. et al. Nocturnal symptoms and severity of disease in COPD. Am. J. Respir. Crit. Care Med. 2001; 163 (5): A906.Littner M ., Auerbach D., Campbell S. et al. The Bronchodilator effects of tiotropium in stable COPD. Am. J. Respir. Crit. Care Med. 1997; 155: A282.Littner M ., Auerbach D., Campbell S. et al. The Bronchodilator effects of tiotropium in stable COPD. Am. J. Respir. Crit. Care Med. 1997; 155: A282.Mahler D.A., Weinberg D.H., Wells C.K. et al. Baseline dyspnea index and transitional dyspnea index: the measurement of dyspnea. Chest 1984; 85: 751-758.Mahler D.A., Weinberg D.H., Wells C.K. et al. Baseline dyspnea index and transitional dyspnea index: the measurement of dyspnea. Chest 1984; 85: 751-758.Mahler D.A., Donohue J.F., Barbee R.A. et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-965.Mahler D.A., Donohue J.F., Barbee R.A. et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-965.Mahler D.A., Montner P., Brazinsky S.A. et al. Tiotropium (SpirivaT): A new, long-acting anticholinergic bronchodilator improves dyspnea in patients with COPD. Am. J. Respir. Crit. Care Med. 2000; 161: A892.Mahler D.A., Montner P., Brazinsky S.A. et al. Tiotropium (SpirivaT): A new, long-acting anticholinergic bronchodilator improves dyspnea in patients with COPD. Am. J. Respir. Crit. Care Med. 2000; 161: A892.McNee W. Oxidants/antioxidants and COPD. Chest 2000; 117: 303S-317S.McNee W. Oxidants/antioxidants and COPD. Chest 2000; 117: 303S-317S.Murray D., Altose M .D. Approaches to slowing the progression of COPD. Curr. Opin. Pulm. Med. 2003; 9 (2): 125-130.Murray D., Altose M .D. Approaches to slowing the progression of COPD. Curr. Opin. Pulm. Med. 2003; 9 (2): 125-130.National COPD Awareness Panel (NCAP). COPD: Achieving best management at the front line of care. J. Respir. Dis. 2002; 23: S1-S52.National COPD Awareness Panel (NCAP). COPD: Achieving best management at the front line of care. J. Respir. Dis. 2002; 23: S1-S52.Pauwels R., Anthonisen N., B ailey W.C. et al. Executive summary of global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Heart, Lung, and Blood Institute-World Health Organization (NHLBI-WHO) workshop report; 2001.Pauwels R., Anthonisen N., B ailey W.C. et al. Executive summary of global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Heart, Lung, and Blood Institute-World Health Organization (NHLBI-WHO) workshop report; 2001.Pauwels R.A., Menjoge S.S., Kesten S. COPD Exacerbations and decline in FEVi: the role of tiotropium. Am. J. Respir. Crit. Care Med. 2001; 163 (5): A280.Pauwels R.A., Menjoge S.S., Kesten S. COPD Exacerbations and decline in FEVi: the role of tiotropium. Am. J. Respir. Crit. Care Med. 2001; 163 (5): A280.Rennard S.I., Serby C.W., Ghafouri M ., et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest. 1996; 110: 62-70.Rennard S.I., Serby C.W., Ghafouri M ., et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest. 1996; 110: 62-70.Rennard S.I., Anderson W., ZuWallack R. et al. Use of a longacting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1087-1092.Rennard S.I., Anderson W., ZuWallack R. et al. Use of a longacting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1087-1092.Rennard S.I., Farmer S.G. COPD in 2001: a major challenge for medicine, the pharmaceutical industry, and society. Chest 2002, 121: 113S-115S.Rennard S.I., Farmer S.G. COPD in 2001: a major challenge for medicine, the pharmaceutical industry, and society. Chest 2002, 121: 113S-115S.Snow V., Lascher S., Mottur-P ilson C., for the Joint Expert Panel on COPD. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 2001; 134: 595-599.Snow V., Lascher S., Mottur-P ilson C., for the Joint Expert Panel on COPD. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 2001; 134: 595-599.Tashkin D., Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123 (5): 144-1449.Tashkin D., Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123 (5): 144-1449.Van Noord J., Bantje Th., Eland M . et al. Superior efficacy of tiotropium compared to ipratropium as a maintenance bronchodilator in COPD. Am. J. Respir. Crit. Care Med. 1999; 159 (3): A525.Van Noord J., Bantje Th., Eland M . et al. Superior efficacy of tiotropium compared to ipratropium as a maintenance bronchodilator in COPD. Am. J. Respir. Crit. Care Med. 1999; 159 (3): A525.Vincken W., van Noord J.A., Greefhorst A.P.M . et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209-216.Vincken W., van Noord J.A., Greefhorst A.P.M . et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209-216.
The authors declare that there are no conflicts of interest present.